Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Laquinimod highlights from Teva Investor Day December 11


Print article Print article
Copyright © Thomson Reuters 2012. All rights reserved.
2012-12-12 08:34:16 -

Lund, Sweden, December 12, 2012 - Active Biotech's (NASDAQ OMX NORDIC: ACTI)
partner Teva Pharmaceutical Industries Ltd. hosted yesterday, December
11, 2012, an investor meeting. Teva has a license to develop and commercialize
Active Biotech's molecule laquinimod.

Laquinimod highlights from the meeting:

· Laquinimod stands to fulfill an unmet treatment need, both as monotherapy and
potentially in combination with other treatments.
· The clinical development program of laquinimod is ongoing. Teva continues to
actively assess the best options for the next phase of clinical development.
Several clinical trials may be initiated as early as 2013:

- A third Phase III clinical trial of laquinimod in relapsing-remitting multiple
sclerosis (RRMS) (CONCERTO).
- Phase III clinical trial of laquinimod in progressive MS.
- Phase II clinical trial of laquinimod in Huntington's disease.
- Phase II clinical trial of 
laquinimod in combination with COPAXONE for RRMS. - Clinical trials of laquinimod in combination with other MS treatments. - Clinical trials of laquinimod for the treatment of additional neurodegenerative diseases. For further information please see www.tevapharm.com. Active Biotech AB (publ) Tomas Leanderson President & CEO For further information, please contact: Hans Kolam, CFO Phone: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. An additional project in clinical development is the orally administered compound 57-57 for Systemic Sclerosis. Please visit www.activebiotech.com for more information. Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00 Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 8:30 a.m. CET on December 12, 2012. Laquinimod highlights from Teva Investor Day December 11: hugin.info/1002/R/1664247/539857.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Active Biotech via Thomson Reuters ONE [HUG#1664247]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser